S
Sarah E. Hudelson
Researcher at Johns Hopkins University School of Medicine
Publications - 34
Citations - 2279
Sarah E. Hudelson is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Viral load & HPTN 052. The author has an hindex of 17, co-authored 33 publications receiving 1926 citations. Previous affiliations of Sarah E. Hudelson include University of North Carolina at Chapel Hill & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Leslie Cottle,Xinyi C. Zhang,Joseph Makhema,Lisa A. Mills,Ravindre Panchia,Sharlaa Faesen,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Max Essex,Sarah E. Hudelson,Andrew D. Redd,Thomas R. Fleming +35 more
TL;DR: The early initiation of ART led to a sustained decrease in genetically linked HIV-1 infections in sexual partners, and was associated with a 93% lower risk of linked partner infection than was delayed ART.
Journal ArticleDOI
Nevirapine (NVP) Resistance in Women with HIV-1 Subtype C, Compared with Subtypes A and D, after the Administration of Single-Dose NVP
Susan H. Eshleman,Donald R. Hoover,Shu Chen,Sarah E. Hudelson,Laura Guay,Anthony Mwatha,Susan A. Fiscus,Francis Mmiro,Philippa Musoke,J. Brooks Jackson,Newton Kumwenda,Taha E. Taha +11 more
TL;DR: The rate of NVP resistance mutations after SD-NVP was significantly higher in women with HIV-1 subtype C than in women in the HIVNET 012 trial with either subtype A or D.
Journal ArticleDOI
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns.
Susan H. Eshleman,Donald R. Hoover,Shu Chen,Sarah E. Hudelson,Laura Guay,Anthony Mwatha,Susan A. Fiscus,Francis Mmiro,Philippa Musoke,J. Brooks Jackson,Newton Kumwenda,Taha E. Taha +11 more
TL;DR: Nevirapine resistance was more frequent in infants with subtype C than with subtypes A and D and in infants who were HIV-1 infected despite single-dose nevirapine prophylaxis, including 18 Ugandan infants.
Journal ArticleDOI
Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 Trial
Susan H. Eshleman,Sarah E. Hudelson,Andrew D. Redd,Lei Wang,R. Debes,Ying Q. Chen,Craig Martens,Stacy M. Ricklefs,Ethan J. Selig,Stephen F. Porcella,Supriya Munshaw,Stuart C. Ray,Estelle Piwowar-Manning,Marybeth McCauley,Mina C. Hosseinipour,Johnstone Kumwenda,James Hakim,Suwat Chariyalertsak,Guy de Bruyn,Beatriz Grinsztejn,Nagalingeswaran Kumarasamy,Joseph Makhema,Kenneth H. Mayer,José Henrique Pilotto,Breno Santos,Thomas C. Quinn,Thomas C. Quinn,Myron S. Cohen,James P. Hughes,James P. Hughes +29 more
TL;DR: The association of early ART and reduced HIV transmission was stronger when the analysis included only linked events, and underscores the importance of assessing the genetic linkage of HIV seroconversion events in HIV prevention studies involving serodiscordant couples.
Journal ArticleDOI
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial
Rami Kantor,Laura M. Smeaton,Saran Vardhanabhuti,Sarah E. Hudelson,Carol L. Wallis,Srikanth Tripathy,Mariza G. Morgado,Shanmugham Saravanan,Pachamuthu Balakrishnan,Marissa B Reitsma,Stephen Hart,John W. Mellors,Elias K. Halvas,Beatriz Grinsztejn,Mina C. Hosseinipour,Johnstone Kumwenda,Alberto La Rosa,Umesh G. Lalloo,Javier R. Lama,Mohammed Rassool,Breno Santos,Khuanchai Supparatpinyo,James Hakim,Timothy P. Flanigan,Nagalingeswaran Kumarasamy,Thomas B. Campbell,Susan H. Eshleman +26 more
TL;DR: In this global clinical trial, pretreatment resistance and HIV-1 subtype were independently associated with virologic failure and should be considered whenever feasible.